Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835625 | 0.86 | PDE5A (0.42) | ALDH1A1HPGDMAPTKDM4EPDE5A | |
| SCHEMBL1837903 | 0.85 | CYP1A2 (0.49) | ALDH1A1KDM4EPDE5ASMN1; SMN2 | |
| SCHEMBL198911 | 0.82 | ALDH1A1 (0.60) | ALDH1A1HPGDTDP1PTPRCMAPT | |
| SCHEMBL2491572 | 0.81 | ALDH1A1 (0.43) | ALDH1A1HPGDTDP1PDK2PTPRC | |
| SCHEMBL476858 | 0.79 | APP (0.57) | ALDH1A1HPGDTDP1MAPTKDM4E | |
| SCHEMBL29590338 | 0.78 | ALDH1A1 (0.56) | ALDH1A1HPGDTDP1MAPTL3MBTL1 | |
| SCHEMBL9647686 | 0.78 | ALDH1A1 (0.56) | ALDH1A1HPGDTDP1MAPTL3MBTL1 | |
| SCHEMBL1133363 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HPGDTDP1PDK2PTPRC | |
| SCHEMBL16174477 | 0.77 | PDK2 (0.51) | ALDH1A1HPGDTDP1PDK2PTPRC | |
| SCHEMBL1837526 | 0.77 | MCHR1 (0.41) | ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321244-B1 | IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-8558030-B2 | Process for telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2321244-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010019360-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-0479541-B1 | Iridium-optically active phosphine complex and catalytic production of optically active alcohols therewith | TAKASAGO PERFUMERY CO LTD (JP) | 1995-07-19 | — | — | EP | disclosed |
| US-5210332-A | Iridium-optically active phosphine complex and process for producing optically active alcohols using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1993-05-11 | — | — | US | disclosed |
| EP-0479541-A1 | Iridium-optically active phosphine complex and catalytic production of optically active alcohols therewith | Takasago International Corporation (JP) | 1992-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | HRH3, HRH4, TELO2 | ALDH1A1 2964/4885HPGD 453/4885TDP1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.